Phase 1 and Phase 2 · Exenatide

NCT02975297 trial results

Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial

Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm (Participants), 6 weeks. Exenatide Plus NRT Plus Counseling: 19; Placebo Plus NRT Plus Counseling: 11.

Participants
84
Status
completed
Completed
2020-01-03
Sponsor
The University of Texas Health Science Center, Houston

As posted on ClinicalTrials.gov (NCT02975297), updated at source Jan 28, 2021. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT02975297 measured first

Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppmParticipants · 6 weeks · count of participants
Exenatide Plus NRT Plus Counselingn=41Placebo Plus NRT Plus Counselingn=41
1911
Post-quit Craving as Assessed by the Questionnaire of Smoking Urgesscore on a scale · 6 weeks · mean
Exenatide Plus NRT Plus Counselingn=34Placebo Plus NRT Plus Counselingn=35
17.2(11.0)16.9(9.75)
Withdrawal Symptoms as Assessed by the Wisconsin Smoking Withdrawal Scalescore on a scale · 6 weeks · mean
Exenatide Plus NRT Plus Counselingn=34Placebo Plus NRT Plus Counselingn=35
40.5(18.3)44.5(18.0)
Side effects by arm

Side effects in NCT02975297

Percent of participants affected, 10 weeks. The most common events the registry lists.

EventExenatide Plus NRT Plus CounselingPlacebo Plus NRT Plus Counseling
Any serious event0%0%
Injection site nodule9.8%0%
Pruritus at the site of nicotine patch application0%2.4%
Secondary outcomes

What else it measured

Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppmParticipants · 7 weeks (1 week after end of treatment) · count of participants
Exenatide Plus NRT Plus Counselingn=19Placebo Plus NRT Plus Counselingn=11
157
Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppmParticipants · 10 weeks (4 weeks after end of treatment) · count of participants
Exenatide Plus NRT Plus Counselingn=19Placebo Plus NRT Plus Counselingn=11
94
Post-quit Craving as Assessed by the Questionnaire of Smoking Urgesscore on a scale · 7 weeks (1 week after end of treatment) · mean
Exenatide Plus NRT Plus Counselingn=16Placebo Plus NRT Plus Counselingn=9
13.3(7.86)14.2(8.47)
Post-quit Craving as Assessed by the Questionnaire of Smoking Urgesscore on a scale · 10 weeks (4 weeks after end of treatment) · mean
Exenatide Plus NRT Plus Counselingn=11Placebo Plus NRT Plus Counselingn=4
11.5(5.13)11.2(2.5)
The trial

How NCT02975297 was run

The purpose of this study is to identify a potential new treatment for smoking cessation.

  • Exenatide plus NRT plus counseling: Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
  • Placebo plus NRT plus counseling: Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
Who could join the trial

Inclusion Criteria: * Be English-speaking volunteers who desire to quit smoking and are willing to make a quit attempt during the course of the study; * Have smoked ≥10 cigarettes a day for at least one year and provide a breath carbon monoxide (CO) ≥10 ppm; * Have a negative pregnancy test, if female of childbearing potential; * Have HbA1C levels between 5.7 and 6.4% or BMI of or greater than 25 kg/square meters * Not currently using any therapy for glycemic control (either injectable \[i.e. insulin\] or oral agents); * Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150 mmHg systolic and 45-95 mmHg diastolic; * Have hematology and chemistry laboratory tests that are within reference limits (within 10% above or below), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits; * Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the principal investigator. Exclusion Criteria: * Meet criteria for the following psychiatric and/or substance use disorders as assessed by the Mini International Neuropsychiatric Interview (MINI): items C (current manic or hypomanic episode only), I (alcohol abuse - Alcohol Addendum-past 3 months only; current alcohol dependence), J (substance abuse -Substance Abuse Addendum - past 3 months only; current substance dependence), K (current psychotic disorder or current mood disorder with psychotic features). * Individuals who meet criteria for non-exclusionary psychiatric disorders that are considered clinically unstable and/or unsuitable to participate as determined by the Principal Investigator and/or Study Physician. * Individuals rated as moderate (9-16) to high (17 or greater) on suicidality as assessed by Module B of the MINI. * Have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; * Have type 1 diabetes mellitus; * Have severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia, or worsening angina pectoris); * Have active temporomandibular joint disease; * Have severe gastrointestinal disease (i.e. severe gastroparesis); * Have previous history of pancreatitis or are at risk for pancreatitis; * Have creatinine clearance (CrCl) \< 30; * Have any previous medically adverse reaction to study medications, nicotine, or menthol; * Be pregnant or lactating or unwilling to provide a negative pregnancy test before study entry; * Not using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide); * Have any illness which in the opinion of the primary investigator would preclude safe and/or successful completion of the study.

Published papers

Papers from NCT02975297

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.